Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Otsuka Holdings Co., Ltd.
  6. Summary
    4578   JP3188220002

OTSUKA HOLDINGS CO., LTD.

(4578)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
4148(c) 4131(c) 4075(c) 4130(c) 4153(c) Last
668 800 549 900 856 700 761 500 569 700 Volume
+1.52% -0.41% -1.36% +1.35% +0.56% Change
More quotes
Estimated financial data (e)
Sales 2021 1 476 B 12 981 M 12 981 M
Net income 2021 158 B 1 388 M 1 388 M
Net cash position 2021 280 B 2 465 M 2 465 M
P/E ratio 2021 14,3x
Yield 2021 2,43%
Sales 2022 1 519 B 13 362 M 13 362 M
Net income 2022 157 B 1 380 M 1 380 M
Net cash position 2022 345 B 3 035 M 3 035 M
P/E ratio 2022 14,3x
Yield 2022 2,47%
Capitalization 2 253 B 19 797 M 19 809 M
EV / Sales 2021 1,34x
EV / Sales 2022 1,26x
Nbr of Employees 33 151
Free-Float 75,4%
More Financials
Company
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (64.4% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale... 
Sector
Pharmaceuticals
Calendar
02/10Earnings Release
More about the company
Ratings of Otsuka Holdings Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about OTSUKA HOLDINGS CO., LTD.
2021OTSUKA HOLDINGS CO., LTD. : Ex-dividend day for final dividend
FA
2021Unichem Laboratories Gets US FDA Nod for Aripiprazole Tablets
MT
2021Nikkei rises on chipmakers, energy boost; SoftBank drops
RE
2021OTSUKA HOLDINGS CO., LTD. : 3rd quarter results
CO
2021Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December..
PU
2021Otsuka Holdings Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ending December..
CI
2021GSK says anaemia drug shows positive safety profile
RE
2021GlaxoSmithKline Rebuffs Reports on Potential Bid for Canada's Aurinia Pharmaceuticals
MT
2021Akebia Says Partner Otsuka Files Initial MAA for Vadadustat with European Medicines Age..
MT
2021OTSUKA : ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the T..
BU
2021LUPIN : Gets US FDA's Approval for Brexpiprazole Tablets
MT
2021Sumitomo Dainippon Sells License for Psychiatry and Neurology Compounds to Otsuka for $..
MT
2021Health Care Stocks Closing Slightly Lower After Early Gains
MT
2021Health Care Stocks Unable to Sustain Early Rise
MT
2021OPTIMIZERX : Hires Edward Stelmakh as CFO, COO
MT
More news
News in other languages on OTSUKA HOLDINGS CO., LTD.
2021Tokyo lâche 3% en séance face aux craintes autour du nouveau variant
2021Tokyo plombée par la hausse des taux d'intérêt américains
2021Otsuka Holdings Co., Ltd. révise ses prévisions de bénéfices pour l'exercice financier ..
2021GlaxoSmithKline réfute les rapports sur une offre potentielle pour la société canadienn..
2021Le partenaire d'Akebia, Otsuka, dépose une première AMM pour le vadadustat auprès de l'..
More news
Chart OTSUKA HOLDINGS CO., LTD.
Duration : Period :
Otsuka Holdings Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OTSUKA HOLDINGS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 4 153,00 JPY
Average target price 4 625,00 JPY
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Tatsuo Higuchi President, CEO & Representative Director
Yuko Makino Executive Officer, Manager-Finance & Accounting
Ichiro Otsuka Vice Chairman
Yukitakeshi Matsutani Independent Outside Director
Yasushi Sekiguchi Independent Outside Director